Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Faces Varicella-Zoster Virus Supply Shortage For Vaccine Production

Executive Summary

Merck does not expect problems in the production of bulk varicella-zoster virus vaccine to affect near-term supplies of individual products that contain the virus - the varicella vaccine Varivax, the herpes zoster vaccine Zostavax, and the measles, mumps, rubella and varicella (MMR-V) combination ProQuad
Advertisement

Related Content

Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
Merck Recalls PedvaxHIB Vaccine, Sanofi Steps Up Production To Fill Void
Merck Recalls PedvaxHIB Vaccine, Sanofi Steps Up Production To Fill Void
Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track
Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track
Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products
Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products
Advertisement
UsernamePublicRestriction

Register

PS048078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel